Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bush Administration Kicks Off Medicare Rx Awareness Campaign

This article was originally published in The Pink Sheet Daily

Executive Summary

President Bush personally launched the national outreach effort with a speech touting the upcoming drug benefit. Phase one of the campaign is focused on telling seniors what the MMA means to them; phase two will include more specific information.

You may also be interested in...



Medicare Rx Assistance: CMS Expects 8 Mil. To Automatically Qualify

CMS is mailing letters to notify Medicare/Medicaid dual-eligibles and others that they automatically qualify for help in paying for Part D coverage. Social Security is mailing approximately 19 mil. additional letters and application forms to those who may be eligible for assistance.

Endo’s Lidoderm Mailings Draw FDA Warning Letter For Unsubstantiated Claims

FDA asks Endo to disseminate “corrective messages” to doctors who received the violative promotional materials, which the agency says omit risk information and contain unsubstantiated effectiveness claims.

Efficacy Differences Within Drug Classes Unsupported By Data, FDA's Temple Says

Studies that look for differences in efficacy among members of the same drug class are only performed when necessary for approval, CDER Office of Medical Policy Director Temple tells DIA. While questioning the introduction of "follow-on" compounds, Temple also highlights AstraZeneca's success in achieving a more optimal dose for Nexium.

Topics

UsernamePublicRestriction

Register

LL1135972

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel